Bissan Al-Lazikani, PhD, FRSB, FISCB, MBCS
Department of Genomic Medicine, Division of Cancer Medicine
About Dr. Bissan Al-Lazikani
About Dr. Al-Lazikani
Dr. Al-Lazikani is a data scientist and drug discoverer. She applies data science and machine learning to address key challenges in cancer drug discovery and development. Dr. Al-Lazikani has drug discovery experience in both academia and the biotechnology industry. Through this experience, she encountered the myriad of hurdles faced through drug discovery and development pipelines. Dr Al-Lazikani’s research focuses on bringing the power of Data and Artificial Intelligence to address these hurdles, accelerating drug discovery and de-risking innovation. Specifically, she applies data science approaches to integrate multi-disciplinary and multi-modal data to inform all aspects of cancer translational research; and to develop novel machine learning algorithms that learn from these integrated data. Together, her approaches inform decision-making and experimental design throughout the drug discovery and development pipeline. She led the development of the world’s largest public cancer drug discovery platform (canSAR.ai) to inform target selection and prioritization for drug discovery. She now leads the Therapeutics Data Science Initiative at MD Anderson Cancer Center to maximally exploit data to discovery novel drugs and individualize drugs and drug combinations for patients.
Present Title & Affiliation
Primary Appointment
Co-Lead, Institute for Data Science in Oncology, The University of Texas MD Anderson Cancer Center, Houston, Texas
Director of Therapeutics Data Science, Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Professor, Genomic Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX
Education & Training
Degree-Granting Education
| 1999 | MRC Laboratory of Molecular Biology and Newnham College, Cambridge University, Cambridge, GB, Ph.D. in Structural Computational Biology |
| 1995 | Imperial College, London, GB, M.Sc. in Computer Science |
| 1994 | University College, London, GB, B.Sc. in Molecular Biology |
Experience & Service
Faculty Academic Appointments
Professor, The Institute of Cancer Research, London, 2018 - 2021
Associate Professor, The Institute of Cancer Research, London, 2015 - 2018
Assistant Professor, The Institute of Cancer Research, London, 2009 - 2015
Administrative Appointments/Responsibilities
Chair of Cancer and Drug Discovery Data Science, The Institute of Cancer Research, 2018 - 2021
Head of Data Science, The Institute of Cancer Research, 2016 - 2021
Editorial Activities
Member of Editorial Review Board, Artificial Intelligence in the Life Sciences, 2021 - Present
Member of the Editorial Board, Bioinformatics Advances, 2021 - 2023
Honors & Awards
| 2023 | Elected Fellow of International Society for Computational Biology, International Society for Computational Biology |
| 2021 | John Black Charitable Foundation-Prostate Cancer Foundation Challenge Award |
| 2021 | Elected Fellow of the Royal Society of Biology, Royal Society of Biology |
| 2021 | Cancer Prevention and Research Institute of Texas Scholar |
| 2018 | University of London Leading Women Award |
| 2017 - 2024 | Chartered Member of the British Computing Society, British Computing Society |
| 2016 | Victoria and Vinny Smith – Prostate Cancer Foundation Challenge Award |
| 2012 | AACR Team Science Award, American Association for Cancer Research |
| 2009 | Institute of Cancer Research Career Development Faculty Establishment Funds |
| 1999 | Howard Hughes Postdoctoral Fellowship |
| 1995 | Medical Research Council PhD Scholarship |
Professional Memberships
Selected Presentations & Talks
Local Presentations
- 2026. Can AI Help Find Drugs for Rare Cancers. Invited. Monthly Sarcoma Lecture Series. Houston, Texas, US.
- 2026. Genome and Epigenome: Genomic/Proteomic Technologies and Applications. Invited. MD Anderson Cancer Center & Princess Margaret Cancer Centre Joint Research Symposium. Houston, Texas, US.
- 2026. Virtual Tumor: A multi-scale model of complex cancers for drug repurposing. Invited. IDSO Focus Area Forum. Houston, Texas, US.
- 2026. Data and AI to inform every decision in drug discovery. Invited. Therapeutics Drug Discovery Project Review. Houston, Texas, US.
- 2025. CCSG Experimental Medicine Monthly Series: Artificial Intelligence. Houston, Texas, US.
- 2025. How and When do Drugs Work. Invited. Second Annual Digital Twin Summit - Computational Modeling in Medical Oncology. Houston, Texas, US.
- 2025. Al For Drug Discovery, Development - Cholangiocarcinoma. Invited. Therapeutics Drug Discovery Project Review. Houston, Texas, US.
- 2025. Digital Twins: For Drug Discovery and Precision Medicine. Invited. MD Anderson Cancer Center Research Townhall. Houston, Texas, US.
- 2025. Al For Drug Discovery, Development - Results, Opportunities, and a Reality Check. Invited. Understanding Our Technologies. Houston, Texas, US.
- 2025. New Therapeutic Strategies. Panelist. Innovative Drug Discovery and Development (IDDD) Consortium: 6th Annual GCC Innovative Drug Discovery and Development Conference. Houston, Texas, US.
- 2025. From and to the patient: Forward and reverse translation in drug discovery. Invited. MD Anderson Research Townhall. Houston, Texas, US.
- 2024. Unpacking Digital Twins in Oncology - Challenges and Perspectives. Houston, Texas, US.
- 2024. AI-informed Drug Discovery: Uncovering Hidden Signals. Invited. The University of Texas MD Anderson Cancer Center Grand Rounds. Houston, Texas, US.
- 2023. The Biology & Characteristics of Radiogenomics in Personalized Medicine. Invited. American Association of Physicists in Medicine - Annual Meeting. Houston, Texas, US.
- 2023. Al for Drug Discovery & Repurposing. Invited. Al for Drug Discovery & Repurposing. Houston, TX, US.
- 2023. Power of Data Science in the Development of Innovative Medicines. Invited. 4th Annual GCC Innovative Drug Discovery and Development Conference. Houston, TX.
- 2022. The Patient is the Focus: Breakthroughs from Bench to Bedside, Clinical and Multiomics Integration and High Value Cancer Care. Invited. The Patient is the Focus: Breakthroughs from Bench to Bedside, Clinical and Multiomics Integration and High Value Cancer Care. Houston, TX, US.
- 2022. AI for Therapeutics, Where We Are and Where We Are Going. Invited. 3rd Annual GCC Innovative Drug Discovery and Development Conference. Houston, Texas, US.
- 2022. AI for therapeutics, where we are and where we are going. Invited. AI for therapeutics, where we are and where we are going. Houston, TX, US.
Regional Presentations
- 2025. Closing Data Gaps in AI-Powered Drug Repurposing. Panelist. Nonprofit AI Drug Discovery, Development, and Repurposing. Dallas, Texas, US.
- 2023. Spring Cancer Research Seminar Series. Invited, TX, US.
- 2022. 3rd Annual Research Retreat of the Joint Center for Computational Oncology. Invited. Oden-MD Anderson Cancer Center-TACC Retreat. Austin, TX, US.
- 2022. Drug Discovery. Invited. Galveston, TX, US.
National Presentations
- 2025. Digital twins across scales: Informing cancer drug discovery and development. Invited. Virtual Human Global Summit II. New York, New York, US.
- 2025. Empowering Your AI Applications in Therapeutics Target Discovery. Panelist. The Festival of Genomics & BioData. Boston, Massachusetts, US.
- 2025. Engineering in Drug Development and Therapeutics. Invited. Cancer Engineering: The Convergence of Engineering and Health to Advance Cancer Research and Care. Washington, D.C, District of Columbia, US.
- 2025. Unlocking the Value of Biomedical Digital Twins: From Cutting-Edge Technologies in BioPharma R&D to Personalized Patient Care. Invited. 24th Annual Bio IT World Conference and Expo. Boston, Massachusetts, US.
- 2025. From and to the patient: Forward and reverse transition in drug discovery. Conference. American Association for Cancer Research (AACR) Annual Meeting 2025. Chicago, Illinois, US.
- 2024. Artificial Intelligence – Promises vs. reality for early detection. Invited. 2024 Early Detection of Cancer Conference. San Francisco, CA, US.
- 2024. Digital Twins for Drug Development to Individualized Therapy. Invited. 31st Annual Prostate Cancer Foundation Scientific Retreat. Carlsbad, CA, US.
- 2024. Integrative AI for novel therapeutic discovery. Invited. Medulloblastoma in the Mountains 2024. Tahoe City, California, US.
- 2023. Data-led drug discovery and personalized therapy in the age of AI. Invited. The Tumor Landscape: Translating Mechanism to Therapy. New York City, New York, US.
- 2023. Unmet Needs and Opportunities to Advance Therapies for Rare Cancers. Invited. Molecular Targets and Cancer Therapeutics Conference. Boston, Massachusetts, US.
- 2023. Uncovering hidden therapeutic opportunities for cancer with AI. Invited. EMBL-EBI Workshop on Precision Medicine and AI. Cambridge, England, GB.
- 2023. Adaptive, AI-Augmented Drug Discovery and Development. Invited. Adaptive, AI-Augmented Drug Discovery and Development. San Diego, CA, US.
- 2023. Opportunities and Challenges for Digital Twins in Biomedical Sciences. Invited. National Academies of Sciences, Engineering, and Medicine Digital Twins. Washington, District of Columbia, US.
- 2022. AI in clinical decisions, integrating molecular multi-omics. Invited. Practical Big Data Workshop 2022. Ann Arbor, MI, US.
- 2022. At the junction of biology, chemistry and computer science: AI for cancer therapy. Invited. ACS Annual Barry Honig 80th Birthday Symposium. San Diego, CA, US.
- 2020. Integrating preclinical and clinical datasets to provide optimal, patient-centered care and identify objective therapeutic cancer targets. Invited. AACR Annual Meeting, US.
- 2019. Power of data and AI in drug development for rare cancers. Invited. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics, Chair. Boston, MA, US.
- 2019. Automation, Big Data and Machine Learning in Drug Discovery. Invited. 2019 Bioorganic Chemistry Gordon Research Conference. Andover, NH, US.
- 2018. Harvard Program in Therapeutic Science. Invited. Harvard Program in Therapeutic Science (HiTS). Boston, MA, US.
- 2017. Biological Inputs and Genomics. Invited. The Inaugural AAPM Practical Big Data Workshop. Ann Arbor, Michigan, US.
- 2016. Translational Medicine Informatics and Applications. Invited. Intelligent Systems for Molecular Biology (ISMB) 2016. Orlando, FL, US.
- 2016. Integrative Chemogenomics for Drug Target Selection and Personalised Treatment. Invited. 2016 Gordon Research Conference on Human Single Nucleotide Polymorphisms & Disease. South Hadley, MA, US.
- 2015. Objective, Data-Driven Target Prioritization for Cancer Drug Discovery. Invited. American Association for Cancer Research (AACR) Annual Meeting. Philadelphia, PA, US.
- 2014. canSAR: a multidisciplinary knowledgebase for support of cancer drug discovery. Invited. Beyond The Genome: Cancer Genomics. Boston, MA, US.
- 2014. Advancements in Precision Medicine Treatments, Treatment Models, and Computational Biology Models. Invited. The 21st Annual Prostate Cancer Foundation (PCF) Scientific Retreat. San Diego, CA, US.
- 2014. Big Data and canSAR in Cancer Target and Drug Discovery. Invited. Targeted Anticancer Therapeutics (TAT) 2014 Congress. Washington, DC, US.
- 2011. canSAR: An integrated cancer drug discovery informatics platform allowing systematic target evaluation. Poster. AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics. San Francisco, CA, US.
- 2011. canSAR: An integrated cancer drug discovery informatics platform allowing systematic target evaluation. Invited. AACR-NCI-EORTC International Conference: Molecular Targets and Cancer Therapeutics. San Francisco, CA, US.
International Presentations
- 2026. Agentic AI in Drug Discovery in Rare Cancers. Invited. AACR Special Conference in Cancer Research: Breaking Barriers in the Fight Against Rare Cancers. Vancouver, CA.
- 2026. Making Drug Discoveries for Rare Cancers. Invited. Keystone Symposia on Computational Advances in Drug Discovery. London, GB.
- 2026. Agent AI and the Future of Drug Discovery and Development. Invited. Cancer Research UK Data-driven Cancer Research Conference. Edinburgh, GB.
- 2025. AI for novel targets in uveal melanoma. Invited. ESMO Sarcoma and Rare Cancers Congress. Lugano, CH.
- 2025. Big data and machine learning in drug discovery. Invited. 2025 ESMO Targeted Anticancer Therapies (TAT). Paris, FR.
- 2025. Early Careers in Bioinformatics. Invited. Queen Mary University of London Charterhouse Square Bioinformatics Network.
- 2024. Traditional drug discovery meets AI: Challenges and opportunities. Invited. Childhood Brain Tumour Research in the Era of Big Data. Cambridge, GB.
- 2024. Can AI help discover therapies for rare and complex cancers?. Invited. ICM Symposium: “Machine Learning and AI for Hard-To-Treat Cancers: Datasets, Pipelines and Clinical Implementation”. Cambridge, GB.
- 2024. Precision Medicine in the Era of Big Data. Invited. Cancer Research UK Data-Driven Cancer Research Conference, GB.
- 2024. CRUK is unique in taking risks to back scientists to harness the power of data. Invited. More Research, Less Cancer – Campaign Launch Event. London, GB.
- 2023. Al for uncovering hidden opportunities in cancer therapy. Invited. First Annual CRO-MDA Symposium on Cancer Biology and Precision. Aviano, IT.
- 2023. AI To Identify Hidden Therapeutic Opportunities. Invited. MIM 2023 Meeting. Cape Town, ZA.
- 2020. Principles of high throughput screening for identifying combinations. Invited. ESMO Targeted Anticancer Therapies (TAT 2020). Paris, FR.
- 2019. Making big data work in real world cancer drug discovery and adaptive therapy. Invited. 40 years Cancer Center Freiburg Symposium.
- 2019. Are big data, deep learning and AI methods changing cancer care and research?. Invited. ESMO Congress. Barcelona, ES.
- 2018. Computational research, innovative machine learning, and big data in cancer drug discovery. Invited. 2018 NCRI Annual Conference. Liverpool, GB.
- 2018. Protein dynamics impact on drug discovery. Invited. Biodynamics. London, GB.
- 2018. Objective, data-driven target prioritization for cancer drug discovery. Invited. 2nd CRUK Accelerating Cancer Drug Discovery through structural biology – Open Meeting. London, GB.
- 2018. Integrating rich biomedical datasets in the era of machine learning. Invited. The Festival of Genomics.
- 2017. Target Validation Using Genomics and Informatics. Invited. Wellcome Trust Target Tractability Workshop. Hinxton, Cambridge, GB.
- 2017. Wellcome Trust Translational Bioinformatics Workshop. Invited. Wellcome Trust Translational Bioinformatics Workshop. Cambridge, GB.
- 2017. Developing data-driven technologies and machine-learning systems designed to discover new cancer therapeutics. Invited. Expedia Invited Expert Seminar Series. London, GB.
- 2017. CanSAR: A 3D View of Cancer Drug Discovery. Invited. Annual World Precision Medicine Congress.
- 2017. Conference Concluding Remarks. Invited. International Society for Computational Biology/Intelligent Systems for Molecular Biology, CZ.
- 2017. Big Data and machine learning are revolutionizing the search for life-saving cancer drugs and reshaping the future of healthcare. Invited. The Tomorrow Talks.
- 2017. Power of data and AI in drug development for rare cancers. Invited. The Festival of Genomics, GB.
- 2016. Big Data' Approaches for Novel Anti-Cancer Drug Discovery. Invited. CNIO – La Caixa Foundation Frontiers Meeting Canceromatics III – Tumor Heterogeneity. Madrid, ES.
- 2016. Computers, Biology and a Bit of Social Networking. Invited. Ada Lovelace Day – Finding Ada Conference. London, GB.
- 2016. Big Data Challenges and Opportunities in Cancer Treatment Innovation. Invited. XVIIIth International Conference on the Use of Computers in Radiation Therapy (ICCR 2016), GB.
- 2014. Drugging the DNA Damage Response. Invited. European Molecular Biology Organization Chemical Biology (ECCB). Heidelberg, DE.
- 2014. Data-driven discovery platforms. Invited. Joint Crick-KCL workshop on Modelling and Computation in Biology and Medicine. London, GB.
- 2014. Big Data for Cancer Drug Discovery. Invited. Practicalities of Cellular Analysis, Omics and Informatics Conference. Newcastle, GB.
- 2013. Drugging the Cancer Genome. Invited. Cancer Pharmacogenomics and Targeted Therapies, Wellcome Trust. Cambridge, GB.
- 2013. Drugging the Cancer Genome. Invited. British Pharmacological Society Target Validation Workshop, GB.
- 2012. Computational target discovery and the canSAR knowledgebase. Invited. 29th Annual Genes and Cancer Meeting, GB.
- 2012. Bioanalysis and Clinical Diagnostics. Invited. analytica 2012: 23rd International Trade Fair for Laboratory Technology, Analysis, Biotechnology and analytica Conference, DE.
Formal Peers
- 2026. AI in Drug Discovery. Galveston, Texas, US.
- 2025. AI in Drug Discovery. Galveston, Texas, US.
- 2024. AI In Drug Discovery. Galveston, Texas, US.
- 2023. AI in Drug Discovery. Galveston, Texas, US.
- 2023. AI in Drug Discovery. Galveston, Texas, US.
Grant & Contract Support
| Date: | 2025 - 2030 |
| Title: | MD Anderson Sarcoma SPORE |
| Funding Source: | National Institutes of Health (NIH) |
| Role: | Co-PI |
| ID: | P50CA302482-01 |
| Date: | 2025 - 2027 |
| Title: | Democratizing Agentic AI for Cancer Drug Discovery |
| Funding Source: | Lyda Hill Philanthropies |
| Role: | PI |
| ID: | 00018566 |
| Date: | 2022 - 2026 |
| Title: | Accelerating Drug Discovery and Development |
| Funding Source: | The Commonwealth Foundation for Cancer Research and MD Anderson Cancer Center |
| Role: | PI |
| Date: | 2022 - 2023 |
| Title: | Establishment of the canSAR Platform at The University of Texas MD Anderson Cancer Center |
| Funding Source: | Lyda Hill Philanthropies |
| Role: | PI |
| Date: | 2021 - 2026 |
| Title: | Established Investigators Recruitment Dr. Bissan Al-Lazkani |
| Funding Source: | Cancer Prevention & Research Institute of Texas (CPRIT) |
| Role: | PI |
| ID: | RR210007 |
| Date: | 2019 - 2025 |
| Title: | The Chemical Probes Portal: An Open Resource Empowering High Quality Chemical Biology |
| Funding Source: | Wellcome Trust Biomedical Resources Grant |
| Role: | Co-PI |
| ID: | 212969/Z/18/Z |
| Date: | 2019 - 2021 |
| Title: | Prostate Cancer Patient Profiling for Drug Repositioning and Discovery |
| Funding Source: | Philanthropic award to Rosalind Eels and Bissan Al-Lazikani |
| Role: | Co-PI |
| Date: | 2018 - 2020 |
| Title: | Cancer Research UK Stratified Medicine Paediatrics – SMPaeds |
| Funding Source: | Cancer Research United Kingdom |
| Role: | Co-PI |
| ID: | C3468/A24566 |
| Date: | 2017 - 2022 |
| Title: | Drug Discovery core grant to the ICR’s CRUK Cancer Therapeutic Unit |
| Funding Source: | Cancer Research United Kingdom |
| Role: | Co-PI |
| ID: | C309 / A25144 |
| Date: | 2017 - 2022 |
| Title: | CRUK Centre Award to the ICR and Royal Marsden |
| Funding Source: | Cancer Research United Kingdom |
| Role: | Co-PI |
| ID: | C2739 / A22897 |
| Date: | 2017 - 2022 |
| Title: | Biomedical Research Centre Award to the Royal Marsden and ICR |
| Funding Source: | National Institute of Health Research |
| Role: | Co-PI |
| Date: | 2017 - 2020 |
| Title: | BBSRC ‘FunPDBe’ functional annotation of protein structures |
| Funding Source: | Biotechnology and Biological Sciences Research Council |
| Role: | Co-PI |
| ID: | BB/P024351/1 |
| Date: | 2017 |
| Title: | National Institute for Health Research The Knowledge Hub (C84) |
| Funding Source: | Biomedical Research Centre |
| Role: | PI |
| ID: | C84/ W92368 |
| Date: | 2016 - 2021 |
| Title: | Drug Discovery Committee Strategic Award |
| Funding Source: | Cancer Research United Kingdom |
| Role: | PI |
| ID: | C35696 / A23187 |
| Date: | 2016 - 2019 |
| Title: | PhD studentship: Integrative genomics to improve castration resistant prostate cancer treatment |
| Funding Source: | Prostate Cancer UK |
| Role: | Co-PI |
| ID: | TLD-S15-006 |
| Date: | 2011 - 2017 |
| Title: | CRUK Drug Discovery core grant to the ICR’s CRUK Cancer Therapeutic Unit |
| Funding Source: | Cancer Research United Kingdom |
| Role: | Co-PI |
| ID: | CRUK-A11566_3 |
| Date: | 2008 - 2014 |
| Title: | Wellcome Trust Chemogenomic Strategic Award |
| Funding Source: | Wellcome Trust |
| Role: | Co-PI |
| ID: | WT086151/Z/08/Z |
Selected Publications
Peer-Reviewed Articles
- James ND, Tannock I, N'Dow J, Feng F, Gillessen S, Ali SA, Trujillo B, Al-Lazikani B, Attard G, Bray F, Compérat E, Eeles R, Fatiregun O, Grist E, Halabi S, Á H, Herchenhorn D, Hofman M, Jalloh M, Loeb S, MacNair A, Mahal B, Mendes L, Moghul M, Moore C, Morgans A, Morris M, Murphy D, Murthy V, Nguyen PL, Padhani A, Parker C, Rush H, Sculpher M, Soule H, Sydes MR, Tilki D, Tunariu N, Villanti P, Xie LP. The Lancet Commission on prostate cancer: planning for the surge in cases. Lancet 403(10437):1683-1722, 2024. e-Pub 2024. PMID: 38583453.
- Gilbertson RJ, Behjati S, Böttcher AL, Bronner ME, Burridge M, Clausing H, Clifford H, Danaher T, Donovan LK, Drost J, Eggermont AMM, Emerson C, Flores MG, Hamerlik P, Jabado N, Jones A, Kaessmann H, Kleinman CL, Kool M, Kutscher LM, Lindberg G, Linnane E, Marioni JC, Maris JM, Monje M, Macaskill A, Niederer S, Northcott PA, Peeters E, Plieger-van Solkema W, Preußner L, Rios AC, Rippe K, Sandford P, Sgourakis NG, Shlien A, Smith P, Straathof K, Sullivan PJ, Suvà ML, Taylor MD, Thompson E, Vento-Tormo R, Wainwright BJ, Wechsler-Reya RJ, Westermann F, Winslade S, Al-Lazikani B, Pfister SM. The Virtual Child. Cancer Discov 14(4):663-668, 2024. e-Pub 2024. PMID: 38571421.
- Antolin AA, Sanfelice D, Crisp A, Villasclaras Fernandez E, Mica IL, Chen Y, Collins I, Edwards A, Müller S, Al-Lazikani B, Workman P. The Chemical Probes Portal: an expert review-based public resource to empower chemical probe assessment, selection and use. Nucleic Acids Res 51(D1):D1492-D1502, 2023. e-Pub 2023. PMID: 36268860.
- Antolin AA, Clarke PA, Collins I, Workman P, Al-Lazikani B. Evolution of kinase polypharmacology across HSP90 drug discovery. Cell Chem Biol 28(10):1433-1445.e3, 2021. e-Pub 2021. PMID: 34077750.
- Antolin AA, Ameratunga M, Banerji U, Clarke PA, Workman P, Al-Lazikani B. The kinase polypharmacology landscape of clinical PARP inhibitors. Sci Rep 10(1):2585, 2020. e-Pub 2020. PMID: 32066817.
- Workman P, Antolin AA, Al-Lazikani B. Transforming cancer drug discovery with Big Data and AI. Expert Opin Drug Discov 14(11):1089-1095, 2019. e-Pub 2019. PMID: 31284790.
- Wedge DC, Gundem G, Mitchell T, Woodcock DJ, Martincorena I, Ghori M, Zamora J, Butler A, Whitaker H, Kote-Jarai Z, Alexandrov LB, Van Loo P, Massie CE, Dentro S, Warren AY, Verrill C, Berney DM, Dennis N, Merson S, Hawkins S, Howat W, Lu YJ, Lambert A, Kay J, Kremeyer B, Karaszi K, Luxton H, Camacho N, Marsden L, Edwards S, Matthews L, Bo V, Leongamornlert D, McLaren S, Ng A, Yu Y, Zhang H, Dadaev T, Thomas S, Easton DF, Ahmed M, Bancroft E, Fisher C, Livni N, Nicol D, Tavaré S, Gill P, Greenman C, Khoo V, Van As N, Kumar P, Ogden C, Cahill D, Thompson A, Mayer E, Rowe E, Dudderidge T, Gnanapragasam V, Shah NC, Raine K, Jones D, Menzies A, Stebbings L, Teague J, Hazell S, Corbishley C, Group CS, de Bono J, Attard G, Isaacs W, Visakorpi T, Fraser M, Boutros PC, Bristow RG, Workman P, Sander C, Consortium T, Hamdy FC, Futreal A, McDermott U, Al-Lazikani B, Lynch AG, Bova GS, Foster CS, Brewer DS, Neal DE, Cooper CS, Eeles RA. Sequencing of prostate cancers identifies new cancer genes, routes of progression and drug targets. Nat Genet 50(5):682-692, 2018. e-Pub 2018. PMID: 29662167.
- Antolin AA, Tym JE, Komianou A, Collins I, Workman P, Al-Lazikani B. Objective, Quantitative, Data-Driven Assessment of Chemical Probes. Cell Chem Biol 25(2):194-205.e5, 2018. e-Pub 2018. PMID: 29249694.
- Santos R, Ursu O, Gaulton A, Bento AP, Donadi RS, Bologa CG, Karlsson A, Al-Lazikani B, Hersey A, Oprea TI, Overington JP. A comprehensive map of molecular drug targets. ANALYSIS Nat Rev Drug Discov 16(1):19-34, 2017. e-Pub 2017. PMID: 27910877.
- Workman P, Al-Lazikani B. Drugging cancer genomes. Nat Rev Drug Discov 12(12):889-90, 2013. e-Pub 2013. PMID: 24287764.
- Gaulton A, Bellis LJ, Bento AP, Chambers J, Davies M, Hersey A, Light Y, McGlinchey S, Michalovich D, Al-Lazikani B, Overington JP. ChEMBL: a large-scale bioactivity database for drug discovery. Nucleic Acids Res 40(Database issue):D1100-7, 2012. e-Pub 2012. PMID: 21948594.
- Overington JP, Al-Lazikani B, Hopkins AL. How many drug targets are there?. Nat Rev Drug Discov 5(12):993-6, 2006. e-Pub 2006. PMID: 17139284.
Other Articles
- Elizabeth A Coker, Adam Stewart, Bugra Ozer, Anna Minchom, Lisa Pickard, Ruth Ruddle, Suzanne Carreira, Sanjay Popat, Mary O'Brien, Florence Raynaud, Johann de Bono, Bissan Al-Lazikani, Udai Banerji Individualized Prediction of Drug Response and Rational Combination Therapy in NSCLC Using Artificial Intelligence–Enabled Studies of Acute Phosphoproteomic Changes. AACR 21(6):1020-1029, 2022.
Patient Reviews
CV information above last modified September 11, 2026